Navigation Links
Great Point Partners II Sells MaSTherCell Global to Catalent

Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, is pleased to announce that it has signed a definitive agreement to sell GPP II portfolio company, MaSTherCell Global (“MaSTherCell”), a subsidiary of Orgenesis (NASDAQ: ORGS), to Catalent Pharma Solutions, Inc. after significantly growing the business. MaSTherCell, based in Belgium and Houston, Texas, is a leading technology-focused cell and gene therapy contract development and manufacturing (“CDMO”) partner for leading biotechnology and pharmaceutical companies. GPP made a growth equity investment in MaSTherCell in June 2018 alongside Orgenesis, a biopharmaceutical company specializing in the development, manufacturing and processing of technologies and services in the cell and gene therapy industry, and SFPI-FPIM, a Belgian sovereign wealth fund. In eighteen months, MaSTherCell has expanded from a single clinical facility in Belgium to three total facilities in the U.S. and EU, including a commercial manufacturing facility under construction.

Noah Rhodes, Managing Director at GPP commented, “We are very proud of what we accomplished with CEO Darren Head, President Denis Bedoret, our partners Orgenesis and SFPI-FPIM, and the entire MaSTherCell team in just over 18 months. During our ownership, we significantly expanded MaSTherCell’s manufacturing capacity, including establishing a U.S. facility in Houston, Texas, thereby creating a company that can serve biotechnology and pharmaceutical clients globally. We look forward to watching the company continue to grow under Catalent’s stewardship.”

“This is the second time I have had the opportunity to partner with GPP in building a contract development and manufacturing business serving life sciences companies. GPP’s expertise in growing global pharmaceutical services companies and their extensive network in the industry were integral to our success both times,” commented Darren Head, CEO of MaSTherCell.

Vered Caplan, CEO of Orgenesis, said, “When GPP reached out about an investment in our contract development manufacture organization, MaSTherCell, it was clear that they recognized the unique value of the company and the best way to position it for future growth. GPP’s experience bringing European pharma services businesses into the U.S. market was invaluable as we executed our growth plan for MaSTherCell.”

“Our theme-based investment approach helped us identify cell and gene therapy manufacturing as a significant growth area and led us to pursue MaSTherCell as a platform company in this area,” added Eddie Hjerpe, Vice President at GPP.

Founded in 2011, MaSTherCell has a 25,000 square-foot facility in Gosselies, Belgium providing clinical services, and construction is in progress on a dedicated 60,000 square-foot commercial-scale production and fill-finish facility nearby, which is scheduled to open in the fall of 2021 and ultimately add over 250 new jobs to the current team of over 240. Its 32,000 square-foot U.S. facility in Houston, Texas, upon completion of validation activities, will focus on development-scale projects and will employ a team of over 50 experts before the end of the year. MaSTherCell has a growing customer base and offers a unique portfolio of capabilities and technologies that include the development and manufacture of autologous and allogeneic cell therapies, as well as a variety of related analytical services. Its experience includes therapies based on chimeric antibody receptor-engineered T cells (CAR-T), T cell receptors (TCR), tumor-infiltrating lymphocytes (TIL), and mesenchymal stem cells (MSC).

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm, currently with approximately $2.0 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III which has $306 million in committed capital) and public (BioMedical Value Fund family, approximately $1.5 billion) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or

About Orgenesis

Orgenesis (NASDAQ: ORGS) is a biopharmaceutical company specializing in the development, manufacturing and processing of technologies and services in the cell and gene therapy industry. The Company operates through two platforms: (i) a point-of-care (“POCare”) cell therapy platform (“PT”) and (ii) a Contract Development and Manufacturing Organization (“CDMO”) platform conducted through its subsidiary, Masthercell Global. Through its PT business, the Company’s aim is to further the development of Advanced Therapy Medicinal Products (“ATMPs”) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patients. The Company out-licenses these ATMPs through regional partners to whom it also provides regulatory, pre-clinical and training services to support their activity in order to reach patients in a point-of-care hospital setting. Through the Company’s CDMO platform, it is focused on providing contract manufacturing and development services for biopharmaceutical companies. Additional information is available at:


The Belgian Federal Holding and Investment Company (Société Fédérale de Participations et d'Investissement / Federale Participatie- en Investeringsmaatschappij; SFPI-FPIM), was created on November 1, 2006 as a result of a merger between the Federal Participation Company and the Federal Investment Company. The Belgian federal government is SFPI-FPIM’s sole shareholder. SFPI-FPIM centrally manages the federal government’s shareholdings, cooperates with the government on specific projects, and pursues its own investment policy in the interests of the Belgian economy. The core business of SFPI-FPIM is as an investment company, to invest in companies with an attractive added value for society in one of the SFPI-FPIM priority sectors. As a holding company, it acquires equity in companies that are of strategic importance as far as federal policy is concerned, either making use of its own funds or by using funds that the state provides for a project.

About MaSTherCell Global, Inc.

MaSTherCell is dedicated to the industrialization and production of cell and gene therapies for leading biotech innovators. Its facilities enable cell therapy companies to benefit from state-of-the-art infrastructures and world-recognized experts, thus accelerating the arrival of cell therapies on the market. At the heart of MaSTherCell is a team of 240 highly dedicated experts combining strong experience in cGMP cell therapy manufacturing with a technology-focused approach and substantial knowledge of the industry. MaSTherCell’s goal is to help customers providing innovative and affordable treatments to patients, in a fast and cost-efficient way.

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related medicine news :

1. Dr. Richard E. Buckley of MilfordMD Cosmetic Dermatology Surgery & Laser Center Comments on Paula Abdul's Secrets to Looking Great After 50
2. GrowFit Analytics Names Leighton Wolffe President to Help Cannabis Growers Achieve Greater Productivity Through Its Smart Data Analytics Solutions
3. Harbor Retirement Associates (HRA) Certified as a Great Place to Work®
4. Ovation Fertility Co-Founder and CEO Nate Snyder Named EY Entrepreneur Of The Year in Greater Los Angeles
5. Villa Healthcare Earns 2nd Annual Great Place to Work® Certification
6. Great Point Partners Makes $22 Million Equity Commitment to Bionova Scientific
7. Specialty Technical Publishers (STP) and Specialty Technical Consultants (STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for Great Britain
8. Becker's Hospital Review Names 100 Hospitals and Health Systems With Great Heart Programs
9. PrognoCIS by Bizmatics Is Now Live With GHH (Greater Houston Healthconnect) Which Is One of the Largest Public Health Information Exchanges (HIEs) in the Country
10. Silverado Named One of the 2018 Best Workplaces for Aging Services by Great Place to Work® and FORTUNE
11. Smile Brands Inc. Honored As Gold Stevie® Award Winner in 2018 Stevie Awards for Great Employers
Post Your Comments:
(Date:9/1/2020)... MESA, Calif. (PRWEB) , ... September 01, 2020 , ... ... the “safe side”, the Cohn Health Institute has taken this time to ... In celebration of its 30th Anniversary, the Cohn Health Institute will be relaunching its ...
(Date:8/31/2020)... ... August 31, 2020 , ... Cardiothoracic surgeons at Allegheny ... from Carnegie Mellon University (CMU) to develop a new heart monitoring device designed ... heart surgery. , The AGH/CMU team was recently awarded a “Trailblazer” grant from ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... Just found out your dear friend has ... heartbreaking when your friend or family member shares their diagnosis. Once the shock wears off, ... say the wrong thing? What are the best ways to help? Words are failing me. ...
(Date:8/31/2020)... ... ... Want to get moving, break up your routine, and make a difference ... launch its fourth annual STEPtember campaign in the United States to raise funds and ... are at this moment — encouraging people to move in the ways that work ...
(Date:8/31/2020)... , ... August 31, 2020 , ... ... innovative higher-learning opportunities through high-quality, career-relevant, and affordable online education – is proud ... . , Among the first of its kind in the nation, the ...
Breaking Medicine News(10 mins):
(Date:8/26/2020)... ... August 26, 2020 , ... AseptiScope, a privately funded San Diego, California based, ... by MedTech Outlook. , “AseptiScope is pleased to receive this recognition,” said ... wear gloves on their hands, goggles on their eyes, covers on their shoes, and ...
(Date:8/26/2020)... WALHALLA, N.D. (PRWEB) , ... August 26, 2020 , ... ... too familiar with the daily routine for preventing the Coronavirus. Wear a mask, keep ... author and fiber advocate Dr. Denis Burkitt said it best in 1977, “How much ...
(Date:8/26/2020)... ... August 26, 2020 , ... ... of Claude E. Hooton as President and Chief Executive Officer effective immediately. Dr. ... of the company’s Board of Managers. , Mr. Hooton, a seasoned business ...
Breaking Medicine Technology: